FY2025 · ended Dec 31, 2025 · Revenue $201.49M, +0.5% YoY · Filed Feb 26, 2026
Cytek Biosciences, Inc. (CTKB) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $201.5 million and a net loss of $66.5 million. Free cash flow was -$8.8 million. As of Sep 30, 2026 it held $255.9 million in cash and investments and $16.2 million in total debt.
Revenue (TTM)
$207.65M
+5.5% vs year-ago TTM
Net income
$-66.54M
-1005.3% vs prior year
Operating cash flow (TTM)
$-6.59M
-243.6% vs year-ago TTM
Free cash flow (TTM)
$-13.48M
-128.7% vs year-ago TTM
EPS (TTM)
$-0.63
-527.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
128.55M
+0.4% vs prior year
Net cash
$239.66M
as of Sep 30, 2026
Operating margin
-21.1%
FY 2026
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- CTKB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fremont, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1831915
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $201.5M | $200.5M | $193.0M | $164.0M | $128.0M |
| Operating income | -$40.4M | -$20.5M | -$27.8M | -$1.8M | $9.2M |
| Net income | -$66.5M | -$6.0M | -$12.1M | $2.5M | $3.0M |
| Diluted EPS | — | — | -$0.09 | $0.02 | $0.00 |
| Operating cash flow | -$4.7M | $25.4M | $5.3M | -$12.2M | $4.6M |
| Free cash flow | -$8.8M | $21.9M | $633,000 | -$22.0M | $266,000 |
| Total assets | $461.5M | $499.5M | $494.5M | $519.5M | $463.3M |
| Total liabilities | $119.8M | $103.8M | $101.4M | $93.9M | $57.9M |
| Stockholders' equity | $341.7M | $395.7M | $393.1M | $425.5M | $405.4M |
| Cash and investments | $261.5M | $277.9M | $262.4M | $341.1M | $364.6M |
| Total debt | $16.9M | $11.3M | $11.9M | $15.2M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 29, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 24, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
All 464 Cytek Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.